Condition: Rhabdomyosarcoma, Recurrent, Refractory · Sponsor: Shandong Cancer Hospital and Institute
To evaluate the efficacy and safety of pazopanib combined with TGI/CIV chemotherapy in children and adolescents with recurrent or refractory rhabdomyosarcoma.
This description comes directly from the study's public registry record.
Shuai Man, Doctor · 0086-18822026105 · shuai2328@163.com
Always discuss trial participation with your own doctor first.
| No. 440 Jiyan Road, Jinan City, Shandong Province | Jinan, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06816771